Patent Application
20240287107
N,N-dimethyltryptamine (DMT) is a naturally occurring compound found in numerous plant species and botanical preparations, such as the hallucinogenic infusion known as ayahuasca, and classified as a classic serotonergic psychedelic that induces intense modifications in perception, emotion, and cognition in humans. At higher doses, DMT has a rapid onset, intense psychedelic effects, and a relatively short duration of action with an estimated half-life of less than fifteen minutes. Like other hallucinogens in the tryptamine family, DMT binds to serotonin receptors to produce euphoria and psychedelic effects. Unfortunately, DMT is metabolically unstable and is readily converted by monoamine oxidases (MAO's) to indoleacetic acid and N-oxidation metabolites resulting in poor oral bioavailability.
Serotonergic psychedelics have also demonstrated promising antidepressant, anxiolytic, and anti-addictive properties.
There remains a need for improved prodrugs of tryptamines, such as N,N-dimethyltryptamine (DMT).
In one aspect, the present disclosure provide a compound of Formula (I-A):
or a pharmaceutically acceptable salt thereof,
wherein:
A is N or C—VR16;
B is N or C—YR4;
E is N or C—ZR5, wherein no more than two of A, B, and E are N;
W is O, S, or NR6;
V, X, Y, and Z are each independently absent, O, S, or NH;
R1 and R2 are each independently H, D, deuterated alkyl, optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted heteroalkyl;
R3, R4, R5, and R16 are each independently H, D, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heteroalkyl, or —P(O)(OH)2;
R6 is H, optionally substituted alkyl, optionally substituted cycloalkyl, alkylene-optionally substituted cycloalkyl, or optionally substituted heteroalkyl;
R7 and R8 are each independently H, D, halogen, optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted heteroalkyl, or R7 and R8 taken together with the atom to which they are attached form an optionally substituted cycloalkyl ring;
R9 and R10 are each independently H, D, halogen, optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted heteroalkyl, or R9 and R10 taken together with the atom to which they are attached form an oxo;
R11 and R12 are each independently alkyl, deuterated alkyl, —O−, —OH, —OD, —O-alkyl, —O-cycloalkyl, —O-alkylene-cycloalkyl, —O-aryl, or —OM, wherein M is a pharmaceutically acceptable cation, or R11 and R12 together with the atoms to which they are attached form a heterocyclyl, and the alkyl, cycloalkyl, aryl and heterocyclyl are each optionally substituted;
R13 is H, D, halogen, deuterated alkyl, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl, alkylene-optionally substituted aryl, —C(O)-(alkylene- optionally substituted aryl), or —O—C(O)—NHR15, or R11 and R13 taken together with the atoms to which they are attached form an optionally substituted heterocyclic ring comprising 4-7 carbon atoms;
R14 is H, D, halogen, haloalkyl, —OH, an optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted heteroalkyl; and
R15 is H, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl.
In one aspect, the present disclosure provides a compound of Formula (I-B):
or a pharmaceutically acceptable salt thereof,
wherein:
A is N or CH;
B is N or C—YR4;
E is N or C—ZR5, wherein no more than two of A, B, and E are N;
W is O, S, or NR6;
X, Y, and Z are each independently absent, O, S, or NH;
R1 and R2 are each independently H, D, optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted heteroalkyl;
R3, R4, and R5 are each independently H, D, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heteroalkyl, or —P(O)(OH)2;
R6 is H, optionally substituted alkyl, optionally substituted cycloalkyl, alkylene-optionally substituted cycloalkyl, or optionally substituted heteroalkyl;
R7 and R8 are each independently H, D, halogen, optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted heteroalkyl, or R7 and R8 taken together with the atom to which they are attached form an optionally substituted cycloalkyl ring;
R9 and R10 are each independently H, D, halogen, optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted heteroalkyl, or R9 and R10 taken together with the atom to which they are attached form an oxo;
R11 and R12 are each independently O−, —OH, —OD, —O-alkyl, —O-cycloalkyl, —O— alkylene-cycloalkyl, —O-aryl, or —OM, wherein M is a pharmaceutically acceptable cation, or R11 and R12 together with the atoms to which they are attached form a heterocyclyl, and the alkyl, cycloalkyl, aryl and heterocyclyl are each optionally substituted;
R13 is H, D, halogen, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl, alkylene-optionally substituted aryl, —C(O)-(alkylene- optionally substituted aryl), or —O—C(O)—NHR15, or R11 and R13 taken together with the atoms to which they are attached form an optionally substituted heterocyclic ring comprising 4-7 carbon atoms;
R14 is H, D, halogen, —OH, an optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted heteroalkyl; and
R15 is H, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl.
In another aspect, the present disclosure provides a compound of Formula (II-A): compound of Formula (II-A):
or a pharmaceutically acceptable salt thereof,
wherein:
A is N or C—VR16;
B is N or C—YR4;
E is N or C—ZR5, wherein no more than two of A, B, and E are N;
W is O, S, or NR6;
V, X, Y, and Z are each independently absent, O, S, or NH;
R1 and R2 are each independently H, D, deuterated alkyl, optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted heteroalkyl;
R3, R4, R5, and R16 are each independently H, D, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heteroalkyl, or —P(O)(OH)2;
R6 is H, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkylene-cycloalkyl, or optionally substituted heteroalkyl;
R7 and R8 are each independently H, D, halogen, optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted heteroalkyl, or R7 and R8 taken together with the atom to which they are attached form an optionally substituted cycloalkyl ring;
R9 and R10 are each independently H, D, halogen, —OH, optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted heteroalkyl, or R9 and R10 taken together with the atom to which they are attached form an oxo;
R12 is —O−, —OH, —OD, —O-alkyl, —O-cycloalkyl, —O-alkylene-cycloalkyl, —O-aryl, or —OM, wherein M is a pharmaceutically acceptable cation, and the alkyl, cycloalkyl, and aryl are each optionally substituted;
R14 is H, D, halogen, —OH, optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted heteroalkyl; and
n is 0, 1, or 2.
In another aspect, the present disclosure provides a compound of Formula (II-B):
or a pharmaceutically acceptable salt thereof,
wherein:
A is N or CH;
B is N or C—YR4;
E is N or C—ZR5, wherein no more than two of A, B, and E are N;
W is O, S, or NR6;
X, Y, and Z are each independently absent, O, S, or NH;
R1 and R2 are each independently H, D, optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted heteroalkyl;
R3, R4, and R5 are each independently H, D, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heteroalkyl, or —P(O)(OH)2;
R6 is H, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkylene-cycloalkyl, or optionally substituted heteroalkyl;
R7 and R8 are each independently H, D, halogen, optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted heteroalkyl, or R7 and R8 taken together with the atom to which they are attached form an optionally substituted cycloalkyl ring;
R9 and R10 are each independently H, D, halogen, —OH, optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted heteroalkyl, or R9 and R10 taken together with the atom to which they are attached form an oxo;
R12 is O−, —OH, —OD, —O-alkyl, —O-cycloalkyl, —O-alkylene-cycloalkyl, —O-aryl, or —OM, wherein M is a pharmaceutically acceptable cation, and the alkyl, cycloalkyl, and aryl are optionally substituted;
R14 is H, D, halogen, —OH, optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted heteroalkyl; and
n is 0, 1, or 2.
In embodiments, the present disclosure provides a pharmaceutical composition comprising a compound of Formula (I-A) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.
In embodiments, the present disclosure provides a pharmaceutical composition comprising a compound of Formula (I-B) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.
In embodiments, the present disclosure provides a pharmaceutical composition comprising a compound of Formula (II-A) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.
In embodiments, the present disclosure provides a pharmaceutical composition comprising a compound of Formula (II-B) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.
Throughout this disclosure, various patents, patent applications and publications are referenced. The disclosures of these patents, patent applications and publications in their entireties are incorporated into this disclosure by reference for all purposes in order to more fully describe the state of the art as known to those skilled therein as of the date of this disclosure. This disclosure will govern in the instance that there is any inconsistency between the patents, patent applications and publications cited and this disclosure.
For convenience, certain terms employed in the specification, examples and claims are collected here. Unless defined otherwise, all technical and scientific terms used in this disclosure have the same meanings as commonly understood by one of ordinary skill in the art to which this disclosure belongs.
The terms “administer,” “administering” or “administration” as used herein refer to administering a compound or pharmaceutically acceptable salt of the compound or a composition or formulation comprising the compound or pharmaceutically acceptable salt of the compound to a patient.
The term “pharmaceutically acceptable salts” includes both acid and base addition salts. Pharmaceutically acceptable salts include those obtained by reacting the active compound functioning as a base, with an inorganic or organic acid to form a salt, for example, salts of hydrochloric acid, sulfuric acid, phosphoric acid, methanesulfonic acid, camphorsulfonic acid, oxalic acid, maleic acid, succinic acid, citric acid, formic acid, hydrobromic acid, benzoic acid, tartaric acid, fumaric acid, salicylic acid, mandelic acid, carbonic acid, etc. The acids that may be used to prepare pharmaceutically acceptable acid addition salts of such basic compounds are those that form non-toxic acid addition salts, i.e., salts containing pharmaceutically acceptable anions, including but not limited to malate, oxalate, chloride, bromide, iodide, nitrate, acetate, tartrate, oleate, fumarate, formate, benzoate, glutamate, methanesulfonate, benzenesulfonate, and p-toluenesulfonate salts. Base addition salts include but are not limited to, ethylenediamine, N-methyl-glucamine, lysine, arginine, ornithine, choline, N,N′-dibenzylethylenediamine, chloroprocaine, diethanolamine, procaine, N-benzylphenethylamine, diethylamine, piperazine, tris-(hydroxymethyl)-aminomethane, tetramethylammonium hydroxide, triethylamine, dibenzylamine, ephenamine, dehydroabietylamine, N-ethylpiperidine, benzylamine, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, ethylamine, basic amino acids, e. g., lysine and arginine dicyclohexylamine and the like. Examples of metal salts include lithium, sodium, potassium, magnesium, calcium salts and the like. Examples of ammonium and alkylated ammonium salts include ammonium, methylammonium, dimethylammonium, trimethylammonium, ethylammonium, hydroxyethylammonium, diethylammonium, butylammonium, tetramethylammonium salts and the like. Examples of organic bases include lysine, arginine, guanidine, diethanolamine, choline and the like. Those skilled in the art will further recognize that acid addition salts may be prepared by reaction of the compounds with the appropriate inorganic or organic acid via any of a number of known methods.
The term “treating” as used herein with regard to a patient, refers to improving at least one symptom of the patient's disorder. In embodiments, treating can be improving, or at least partially ameliorating a disorder or one or more symptoms of a disorder.
The term “preventing” as used herein with regard to a patient or subject, refers to preventing the onset of disease development if none had occurred, preventing the disease or disorder from occurring in a subject or a patient that may be predisposed to the disorder or disease but has not yet been diagnosed as having the disorder or disease, and/or preventing further disease/disorder development if already present.
The term “therapeutically effective” applied to dose or amount refers to that quantity of a compound or pharmaceutical formulation that is sufficient to result in a desired clinical benefit after administration to a patient in need thereof.
When a range of values is listed, it is intended to encompass each value and sub-range within the range. For example, “C1-C6 alkyl” is intended to encompass C1, C2, C3, C4, C5, C6, C1-6, C1-5, C1-4, C1-3, C1-2, C2-6, C2-5, C2-4, C2-3, C3-6, C3-5, C3_4, C4-6, C4-5, and C5-6 alkyl.
“Alkyl” or “alkyl group” refers to a fully saturated, straight or branched hydrocarbon chain having from one to twelve carbon atoms, and which is attached to the rest of the molecule by a single bond. Alkyls comprising any number of carbon atoms from 1 to 12 are included. An alkyl comprising up to 12 carbon atoms is a C1-C12 alkyl, an alkyl comprising up to 10 carbon atoms is a C1-C10 alkyl, an alkyl comprising up to 6 carbon atoms is a C1-C6 alkyl and an alkyl comprising up to 5 carbon atoms is a C1-C5 alkyl. A C1-C5 alkyl includes C5 alkyls, C4 alkyls, C3 alkyls, C2 alkyls and C1 alkyl (i.e., methyl). A C1-C6 alkyl includes all moieties described above for C1-C5 alkyls but also includes C6 alkyls. A C1-C10 alkyl includes all moieties described above for C1-C5 alkyls and C1-C6 alkyls, but also includes C7, C8, C9 and C10 alkyls. Similarly, a C1-C12 alkyl includes all the foregoing moieties, but also includes C11 and C12 alkyls. Non-limiting examples of C1-C12 alkyl include methyl, ethyl, n-propyl, i-propyl, sec-propyl, n-butyl, i-butyl, sec-butyl, t-butyl, n-pentyl, t-amyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, n-undecyl, and n-dodecyl. Unless stated otherwise specifically in the specification, an alkyl group can be optionally substituted.
“Aryl” refers to a hydrocarbon ring system comprising hydrogen, 6 to 18 carbon atoms and at least one aromatic ring, and which is attached to the rest of the molecule by a single bond. For purposes of this disclosure, the aryl can be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which can include fused or bridged ring systems. Aryls include, but are not limited to, aryls derived from aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, fluoranthene, fluorene, as-indacene, s-indacene, indane, indene, naphthalene, phenalene, phenanthrene, pleiadene, pyrene, and triphenylene. Unless stated otherwise specifically in the specification, the “aryl” can be optionally substituted.
“Cycloalkyl” refers to a stable non-aromatic monocyclic or polycyclic fully saturated hydrocarbon consisting solely of carbon and hydrogen atoms, which can include fused, bridged, or spirocyclic ring systems, having from three to twenty carbon atoms (e.g., having from three to ten carbon atoms) and which is attached to the rest of the molecule by a single bond. Monocyclic cycloalkyls include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Polycyclic cycloalkyls include, for example, adamantyl, norbornyl, decalinyl, 7,7-dimethyl-bicyclo[2.2.1]heptanyl, and the like. Unless otherwise stated specifically in the specification, a cycloalkyl group can be optionally substituted.
“Heterocyclyl,” “heterocyclic ring” or “heterocycle” refers to a stable saturated, unsaturated, or aromatic 3- to 20-membered ring which consists of two to nineteen carbon atoms and from one to six heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, and which is attached to the rest of the molecule by a single bond. Heterocyclyl or heterocyclic rings include heteroaryls, heterocyclylalkyls, heterocyclylalkenyls, and hetercyclylalkynyls. Unless stated otherwise specifically in the specification, the heterocyclyl can be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which can include fused, bridged, or spirocyclic ring systems; and the nitrogen, carbon or sulfur atoms in the heterocyclyl can be optionally oxidized; the nitrogen atom can be optionally quaternized; and the heterocyclyl can be partially or fully saturated. Examples of such heterocyclyl include, but are not limited to, dioxolanyl, thienyl[1,3]dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxo-thiomorpholinyl, and 1,1-dioxo-thiomorpholinyl. Unless stated otherwise specifically in the specification, a heterocyclyl group can be optionally substituted.
“Heteroaryl” refers to a 5- to 20-membered ring system comprising hydrogen atoms, one to nineteen carbon atoms, one to six heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, at least one aromatic ring, and which is attached to the rest of the molecule by a single bond. For purposes of this disclosure, the heteroaryl can be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which can include fused or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heteroaryl can be optionally oxidized; the nitrogen atom can be optionally quaternized. Examples include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzothiazolyl, benzindolyl, benzodioxolyl, benzofuranyl, benzooxazolyl, benzothiazolyl, benzothiadiazolyl, benzo[b][1,4]dioxepinyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzothienyl (benzothiophenyl), benzotriazolyl, benzo[4,6]imidazo[1,2-a]pyridinyl, carbazolyl, cinnolinyl, dibenzofuranyl, dibenzothiophenyl, furanyl, furanonyl, isothiazolyl, imidazolyl, indazolyl, indolyl, indazolyl, isoindolyl, indolinyl, isoindolinyl, isoquinolyl, indolizinyl, isoxazolyl, naphthyridinyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl, oxiranyl, 1-oxidopyridinyl, 1-oxidopyrimidinyl, 1-oxidopyrazinyl, 1-oxidopyridazinyl, 1-phenyl-1H-pyrrolyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, quinazolinyl, quinoxalinyl, quinolinyl, quinuclidinyl, isoquinolinyl, tetrahydroquinolinyl, thiazolyl, thiadiazolyl, triazolyl, tetrazolyl, triazinyl, and thiophenyl (i.e. thienyl). Unless stated otherwise specifically in the specification, a heteroaryl group can be optionally substituted.
The term “substituted” used herein means any of the groups described herein (e.g., alkyl, alkenyl, alkynyl, alkoxy, aryl, cycloalkyl, cycloalkenyl, haloalkyl, heterocyclyl, and/or heteroaryl) wherein at least one hydrogen atom is replaced by a bond to a non-hydrogen atoms such as, but not limited to: a halogen atom such as F, Cl, Br, and I; an oxygen atom in groups such as hydroxyl groups, alkoxy groups, and ester groups; a sulfur atom in groups such as thiol groups, thioalkyl groups, sulfone groups, sulfonyl groups, and sulfoxide groups; a nitrogen atom in groups such as amines, amides, alkylamines, dialkylamines, arylamines, alkylarylamines, diarylamines, N-oxides, imides, and enamines; a silicon atom in groups such as trialkylsilyl groups, dialkylarylsilyl groups, alkyldiarylsilyl groups, and triarylsilyl groups; and other heteroatoms in various other groups. “Substituted” also means any of the above groups in which one or more hydrogen atoms are replaced by a higher-order bond (e.g., a double- or triple-bond) to a heteroatom such as oxygen in oxo, carbonyl, carboxyl, and ester groups; and nitrogen in groups such as imines, oximes, hydrazones, and nitriles. For example, “substituted” includes any of the above groups in which one or more hydrogen atoms are replaced with —NRgRh, —NRgC(═O)Rh, —NRgC(═O)NRgRh, —NRgC(═O)ORh, —NRgSO2Rh, —OC(═O)NRgRh, —ORg, —SRg, —SORg, —SO2Rg, —OSO2Rg, —SO2ORg, ═NSO2Rg, and —SO2NRgRh. “Substituted” also means any of the above groups in which one or more hydrogen atoms are replaced with —C(═O)Rg, —C(═O)ORg, —C(═O)NRgRh, —CH2SO2Rg, —CH2SO2NRgRh. In the foregoing, Rg and Rh are the same or different and independently hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, haloalkyl, haloalkenyl, haloalkynyl, heterocyclyl, N-heterocyclyl, heterocyclylalkyl, heteroaryl, N-heteroaryl and/or heteroarylalkyl. “Substituted” further means any of the above groups in which one or more hydrogen atoms are replaced by a bond to an amino, cyano, hydroxyl, imino, nitro, oxo, thioxo, halo, alkyl, alkenyl, alkynyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, haloalkyl, haloalkenyl, haloalkynyl, heterocyclyl, N-heterocyclyl, heterocyclylalkyl, heteroaryl, N-heteroaryl and/or heteroarylalkyl group. In addition, each of the foregoing substituents can also be optionally substituted with one or more of the above substituents.
The present disclosure provides compounds that are prodrugs of tryptamines and related scaffolds, for example N,N-dimethyltryptamine (DMT) as well as pharmaceutical compositions thereof.
DMT is metabolically unstable and is readily converted by monoamine oxidases (MAO's) to indoleacetic acid and N-oxidation metabolites resulting in poor oral bioavailability. In embodiments, the compounds of the present disclosure allow for the controlled release of DMT. Advantages of compounds of the present disclosure may include increased metabolic stability, increased absorption, decreased maximal plasma concentrations of parent drug DMT over time, and less frequent dosing. In embodiments, compounds of the present disclosure prevent or inhibit N-oxidation to promote oral bioavailability and increased exposure.
In embodiments, the DMT compounds of the present disclosure comprise a phosphate moiety, a phosphonate moiety, or a derivate thereof. Without being bound by theory such compounds may for example, increase bioavailability by virtue of active transport of the prodrug in the small intestine by high-capacity nutrient transporters, including mono-carboxylate transporter-1 (MCT-1). The DMT prodrugs disclosed herein may also reduce abuse potential by preventing absorption by snorting or insufflation.
In embodiments, the present disclosure provides a compound of Formula (I-A):
or a pharmaceutically acceptable salt thereof,
wherein:
E is N or C—ZR5, wherein no more than two of A, B, and E are N;
V, X, Y, and Z are each independently absent, O, S, or NH;
R1 and R2 are each independently H, D, deuterated alkyl, optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted heteroalkyl;
R3, R4, R5, and R16 are each independently H, D, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heteroalkyl, or —P(O)(OH)2;
R6 is H, optionally substituted alkyl, optionally substituted cycloalkyl, alkylene- optionally substituted cycloalkyl, or optionally substituted heteroalkyl;
R7 and R8 are each independently H, D, halogen, optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted heteroalkyl, or R7 and R8 taken together with the atom to which they are attached form an optionally substituted cycloalkyl ring;
R9 and R10 are each independently H, D, halogen, optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted heteroalkyl, or R9 and R10 taken together with the atom to which they are attached form an oxo;
R11 and R12 are each independently alkyl, deuterated alkyl, O−, —OH, —OD, —O-alkyl, —O— cycloalkyl, —O-alkylene-cycloalkyl, —O-aryl, or —OM, wherein M is a pharmaceutically acceptable cation, or R11 and R12 together with the atoms to which they are attached form a heterocyclyl, and the alkyl, cycloalkyl, aryl and heterocyclyl are each optionally substituted;
R13 is H, D, halogen, deuterated alkyl, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl, alkylene-optionally substituted aryl, —C(O)-(alkylene- optionally substituted aryl), or -G-C(O)—NHR15, or R11 and R13 taken together with the atoms to which they are attached form an optionally substituted heterocyclic ring comprising 4-7 carbon atoms;
R14 is H, D, halogen, haloalkyl, —OH, an optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted heteroalkyl; and
R15 is H, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl.
In embodiments, the present disclosure provides a compound of Formula (II-A):
or a pharmaceutically acceptable salt thereof,
wherein:
E is N or C—ZR5, wherein no more than two of A, B, and E are N;
V, X, Y, and Z are each independently absent, O, S, or NH;
R1 and R2 are each independently H, D, deuterated alkyl, optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted heteroalkyl;
R3, R4, R5, and R15 are each independently H, D, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heteroalkyl, or —P(O)(OH)2;
R6 is H, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkylene-cycloalkyl, or optionally substituted heteroalkyl;
R7 and R8 are each independently H, D, halogen, optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted heteroalkyl, or R7 and R8 taken together with the atom to which they are attached form an optionally substituted cycloalkyl ring;
R9 and R10 are each independently H, D, halogen, —OH, optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted heteroalkyl, or R9 and R10 taken together with the atom to which they are attached form an oxo;
R12 is O−, —OH, —OD, —O-alkyl, —O-cycloalkyl, —O-alkylene-cycloalkyl, —O-aryl, or —OM, wherein M is a pharmaceutically acceptable cation, and the alkyl, cycloalkyl, and aryl are optionally substituted;
R14 is H, D, halogen, —OH, optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted heteroalkyl; and
n is 0, 1, or 2.
In embodiments, A is N. In embodiments, A is C—VR16.
In embodiments, B is N. In embodiments, B is C—YR4.
In embodiments, E is N. In embodiments, E is C—ZR5.
In embodiments, W is NR6 or O. In embodiments, W is NR6 or S. In embodiments, W is O or S. In embodiments, W is NR6. In embodiments, W is O. In embodiments, W is S.
In embodiments, V, X, Y, and Z are each independently absent, O, S, or N(C1-5)alkyl. In embodiments, V, X, Y, and Z are each independently absent or O. In embodiments, V, X, Y, and Z are each independently absent or NH. In embodiments, V, X, Y, and Z are each independently absent or S. In embodiments, V, X, Y, and Z are each absent.
In embodiments, X is O, and V, Y and Z are absent. In embodiments, Y is G, and V, X and Z are absent. In embodiments, Z is O, and V, X and Y are absent. In embodiments, V is G, and X, Y, and Z are absent. In embodiments, X is S, and V, Y and Z are absent. In embodiments, Y is S, and V, X and Z are absent. In embodiments, Z is S, and V, X and Y are absent. In embodiments, V is S, and X, Y, and Z are absent. In embodiments, X is NH, and V, Y and Z are absent. In embodiments, Y is NH, and V, X and Z are absent. In embodiments, Z is NH, and V, X and Y are absent. In embodiments, V is NH, and X, Y, and Z are absent. In embodiments, X is N(C1-5)alkyl, and V, Y and Z are absent. In embodiments, Y is N(C1-5)alkyl, and V, X and Z are absent. In embodiments, Z is N(C1-5)alkyl, and V, X and Y are absent. In embodiments, V is N(C1-5)alkyl, and X, Y, and Z are absent.
In embodiments, R1 and R2 are each independently H, optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted heteroalkyl. In embodiments, R1 and R2 are each independently H, optionally substituted C1-5alkyl, optionally substituted C3-6cycloalkyl, or optionally substituted C1-5cycloalkyl heteroalkyl. In some embodiments, R1 and R2 are each independently H or alkyl. In some embodiments, R1 and R2 are each independently alkyl or deuterated alkyl. In some embodiments, R1 and R2 are each independently H or deuterated alkyl. In embodiments, R1 and R2 are each independently H or C1-5alkyl. In embodiments, R1 and R2 are each independently H or deuterated C1-5alkyl. In embodiments, R1 and R2 are each independently alkyl or deuterated C1-5alkyl. In embodiments, R1 and R2 are each alkyl. In embodiments, R1 and R2 are each deuterated alkyl. In embodiments, R1 and R2 are each C1-5alkyl. In embodiments, R1 and R2 are each deuterated C1-5alkyl. In embodiments, R1 and R2 are each independently methyl, ethyl, or isopropyl. In embodiments, R1 and R2 are each independently deuterated methyl, deuterated ethyl, or deuterated isopropyl. In embodiments, R1 and R2 are each methyl. In embodiments, R1 and R2 are each deuterated methyl. In embodiments, R1 and R2 taken together with the nitrogen to which they are attached form a 4- to 6-membered heterocyclyl, e.g., azetidine, pyrrolidine, or piperidine.
In embodiments, R3, R4, R5, and R16 are each independently H, D, optionally substituted C1-5alkyl, optionally substituted C3-6cycloalkyl, optionally substituted C1-5heteroalkyl, —P(O)(OC1-5alkyl)2, —P(O)(OPh)2, or —P(O)(OH)2. In embodiments, R3, R4, R5, and R16 are each independently H, optionally substituted C1-5alkyl, optionally substituted C3-6cycloalkyl, optionally substituted C1-5heteroalkyl, —P(O)(OC1-5alkyl)2, —P(O)(OPh)2, or —P(O)(OH)2. In embodiments, R3, R4, R5, and R16 are each independently H, optionally substituted C1-5alkyl, optionally substituted C3-6cycloalkyl, —P(O)(OC1-5alkyl)2, —P(O)(OPh)2, or —P(O)(OH)2. In embodiments, R3, R4, R5, and R16 are each independently H, optionally substituted C1-5alkyl, optionally substituted C3-6cycloalkyl, or —P(O)(OH)2. In embodiments, R3, R4, R5, and R16 are each independently H, optionally substituted C1-5alkyl, or —P(O)(OH)2. In embodiments, the C1-5alkyl is methyl, ethyl, propyl, isopropyl, or t-butyl. In embodiments, the C1-5alkyl is methyl, ethyl, or isopropyl. In embodiments, R3, R4, R5, and R16 are each H.
In embodiments, R3 is optionally substituted C1-5alkyl or —P(O)(OH)2, and R4, R5, and R16 are each H. In embodiments, R4 is optionally substituted C1-5alkyl or —P(O)(OH)2, and R3, R5, and R16 are each H. In embodiments, R5 is optionally substituted C1-5alkyl or —P(O)(OH)2, and R3, R4, and R16 are each H. In embodiments, R16 is optionally substituted C1-5alkyl or —P(O)(OH)2, and R3, R4, and R5 are each H. In embodiments, the C1-5alkyl is methyl, ethyl, propyl, isopropyl, or t-butyl. In embodiments, the C1-5alkyl is methyl, ethyl, or isopropyl.
In embodiments, X is absent, and R3 is H, halogen, optionally substituted C1-5alkyl, optionally substituted C3-6cycloalkyl, or —P(O)(OH)2. In embodiments, Y is absent, and R4 is H, halogen, optionally substituted C1-5alkyl, optionally substituted C3-6cycloalkyl, or —P(O)(OH)2. In embodiments, Z is absent, and R3 is H, halogen, optionally substituted C1-5alkyl, optionally substituted C3-6cycloalkyl, or —P(O)(OH)2. In embodiments, V is absent, and R16 is H, halogen, optionally substituted C1-5alkyl, optionally substituted C3-6cycloalkyl, or —P(O)(OH)2. In embodiments, the C1-5alkyl is methyl, ethyl, propyl, isopropyl, or t-butyl. In embodiments, the C1-5alkyl is methyl, ethyl, or isopropyl. In embodiments, the halogen is F, Cl, or Br.
In embodiments, R6 is H, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkylene-cycloalkyl, optionally substituted alkylene-heterocyclyl, or optionally substituted alkylene-aryl. In embodiments, R6 is H, optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted alkylene-cycloalkyl. In embodiments, the optionally substituted alkyl is an optionally substituted C1-5alkyl. In embodiments, the optionally substituted cycloalkyl is an optionally substituted C3-6cycloalkyl. In embodiments, the optionally substituted aryl is an optionally substituted phenyl. In embodiments, the optionally substituted heterocyclyl is an optionally substituted 4- to 6-membered heterocyclyl, e.g., an azetidine, pyrrolidine, piperidine, morpholine, thiomorpholine, piperazine, each of which is optionally substituted. In embodiments, the optionally substituted alkylene is an optionally substituted C1-3alkylene. In embodiments, the optionally substituted alkylene is an optionally substituted methylene. In embodiments, R6 is H, C1-5alkyl, C3-6cycloalkyl or C(═O)(C1-5 alkyl). In embodiments, R6 is H, C1-5alkyl, or C3-8 cycloalkyl. In embodiments, R6 is H or C1-5alkyl. In embodiments, R6 is H. In embodiments, R6 is C1-5alkyl. In embodiments, the C1-5alkyl is methyl, ethyl, propyl, isopropyl, or t-butyl. In embodiments, the optionally substituted C1-5alkyl is —C(O)—C1-4alkyl, —C(O)—N(H)(C1-4alkyl), or —C(O)—OC1-4alkyl.
In embodiments, R7 and R8 are each independently H, halogen, optionally substituted alkyl, —OH, optionally substituted —O-alkyl or optionally substituted —O— cycloalkyl. In embodiments, R7 and R8 are each independently H, halogen, optionally substituted C1-5alkyl, —OH, optionally substituted —OC1-5alkyl, or optionally substituted —O—C3-6cycloalkyl. In embodiments, R7 and R8 are each independently H or optionally substituted C1-5alkyl. In embodiments, R7 and R8 are each H. In embodiments, R7 and R8 are each optionally substituted C1-5alkyl. In embodiments, R7 and R8 are each halogen. In embodiments, the halogen is F. In embodiments, the C1-5alkyl is methyl, ethyl, or isopropyl. In embodiments, the C1-5alkyl is methyl. In embodiments, the C1-5alkyl is ethyl.
In embodiments, R7 and R8 taken together with the atom to which they are attached form an oxo or an optionally substituted cycloalkyl ring. In embodiments, R7 and R8 taken together with the atom to which they are attached form an oxo. In embodiments, R7 and R8 taken together with the atom to which they are attached form an optionally substituted cycloalkyl ring. In embodiments, the optionally substituted cycloalkyl ring is an optionally substituted C3-6cycloalkyl ring. In embodiments, the optionally substituted cycloalkyl ring is an optionally substituted cyclopropyl. In embodiments, R7 is H and R5 is optionally substituted C1-5alkyl. In embodiments, R7 is H and R5 is F. In embodiments, R7 is H and R5 is —OH. In embodiments, R7 is H and R5 is —OCH3. In embodiments, R7 is F and R5 is F. In embodiments, R7 and R8 are each optionally substituted C1-5alkyl. In embodiments, the C1-5alkyl is methyl.
In embodiments, R9 and R10 are each independently H, halogen, optionally substituted alkyl, —OH, optionally substituted —O-alkyl or optionally substituted —O— cycloalkyl. In embodiments, R9 and R10 are each independently H, halogen, optionally substituted C1-5alkyl, —OH, optionally substituted —OC1-5alkyl, or optionally substituted —O—C3-6cycloalkyl. In embodiments, R9 and R10 are each independently H or optionally substituted C1-5alkyl. In embodiments, R9 and R10 are each H. In embodiments, R9 and R10 are each optionally substituted C1-5alkyl. In embodiments, R9 and R10 are each halogen. In embodiments, the halogen is F. In embodiments, the C1-5alkyl is methyl, ethyl, or isopropyl. In embodiments, the C1-5alkyl is methyl. In embodiments, the C1-5alkyl is ethyl.
In embodiments, R9 and R10 taken together with the atom to which they are attached form an optionally substituted cycloalkyl ring. In embodiments, the optionally substituted cycloalkyl ring is an optionally substituted C3-6cycloalkyl ring. In embodiments, the optionally substituted cycloalkyl ring is an optionally substituted cyclopropyl. In embodiments, R9 is H and R10 is optionally substituted C1-5alkyl. In embodiments, R9 is H and R10 is F. In embodiments, R9 is H and R10 is —OH. In embodiments, R9 is H and R10 is —OCH3. In embodiments, R9 and R10 are each F. In embodiments, R9 and R10 are each optionally substituted C1-5alkyl. In embodiments, the C1-5alkyl is methyl.
In embodiments of Formula (I-A), R11 and R12 are each independently alkyl, deuterated alkyl, O−, —OH, optionally substituted —O-alkyl, optionally substituted —O-cycloalkyl, optionally substituted —O-alkylene-cycloalkyl, optionally substituted —O-aryl, or —OM, wherein M is a pharmaceutically acceptable cation. In embodiments, the optionally substituted —O-alkyl is an optionally substituted —O-haloalkyl, a hemiaminal, an acetal, or an amino acid residue. In embodiments, R11 and R12 are each independently O−, —OH, optionally substituted —O—C1-5alkyl, optionally substituted —O—C1-5haloalkyl, optionally substituted —O—C3-6cycloalkyl, or -OM. In embodiments, R11 and R12 are each independently O−, —OH, optionally substituted —O—C1-5alkyl, optionally substituted —O—C1-5haloalkyl, or -OM. In embodiments, R11 is O− and R12 is —OH, optionally substituted —O—C1-5alkyl, optionally substituted —O—C1-5haloalkyl, or -OM. In embodiments, R11 and R12 are each optionally substituted —O—C1-5alkyl. In embodiments, R11 and R12 are each optionally substituted —O—C1-3alkyl. In embodiments, R11 and R12 are each independently —OMe, —OEt, —OiPr, or -OtBu. In embodiments, R11 and R12 are each optionally substituted —O—C1-5haloalkyl. In embodiments, the —O—C1-5haloalkyl is —OCH3, —OCH2F, —OCHF2, or —OCH2CF3. In embodiments, the —O—C1-5haloalkyl is a —OCH2CF3. In embodiments, R11 and R12 are each independently alkyl, deuterated alkyl, O−, —OH, —OD, —O-alkyl, or —O— cycloalkyl. In embodiments, R11 and R12 are each independently alkyl or deuterated alkyl. In embodiments, M is Na+, K+, NH4+, or Ca+2. In embodiments, M is Na+, K+, or NH4+.
In embodiments of Formula (I-A), R11 and R12 taken together with the atoms to which they are attached form a heterocyclyl. In embodiments, R11 and R12 taken together with the atoms to which they are attached form a 5- to 12-membered heterocyclyl. In embodiments, the heterocyclyl has the structure:
In embodiments of Formula (II-A), R12 is O−, —OH, optionally substituted —O-alkyl, optionally substituted —O-cycloalkyl, optionally substituted —O-alkylene-cycloalkyl, optionally substituted —O-aryl, or —OM, wherein M is a pharmaceutically acceptable cation. In embodiments, the optionally substituted —O-alkyl is an optionally substituted —O-haloalkyl, a hemiaminal, an acetal, or an amino acid residue. In embodiments, R12 is O−, —OH, —O-alkyl, —O-haloalkyl, —O-cycloalkyl, or -OM. In embodiments, R12 is O−, —OH, optionally substituted —O-alkyl, optionally substituted —O-haloalkyl, or -OM. In embodiments, R12 is O−, optionally substituted —O-alkyl, or optionally substituted —O-haloalkyl. In embodiments, R12 is optionally substituted —O-alkyl. In embodiments, the optionally substituted —O-alkyl is an optionally substituted —O—C1-5alkyl. In embodiments, the —O-alkyl is —OMe, —OEt, —OiPr, or -OtBu. In embodiments, R12 is —O-haloalkyl. In embodiments, the optionally substituted —O-haloalkyl is optionally substituted —O—C1-5haloalkyl. In some embodiments, the —O-haloalkyl is —OCH2CF3. In embodiments, R12 is O−, —OH, —O—C1-5alkyl, —O—C1-5haloalkyl, —O—C3-6cycloalkyl, or -OM. In embodiments, M is Na+, K+, NH4+, or Ca+2. In embodiments, M is Na+, K+, or NH4+. In embodiments, the —O-alkyl is —OMe, —OEt, —OiPr, or -OtBu. In embodiments, the —O—C1-5haloalkyl is —OCH3, —OCH2F, —OCHF2, or —OCH2CF3. In embodiments, the —O—C1-5haloalkyl is —OCH2CF3.
In embodiments, R13 is H, D, or C1-5alkyl. In embodiments, R13 is H or —C1-5alkyl. In embodiments, the C1-5alkyl is methyl, ethyl, propyl, isopropyl, or butyl. In embodiments, R13 is H, methyl, ethyl, or isopropyl.
In embodiments of Formula (I), R11 and R13 taken together with the atoms to which they are attached form an optionally substituted heterocyclic ring comprising 4-7 carbon atoms. In embodiments, R1 and R13 taken together with the atoms to which they are attached form an optionally substituted 5-to 7-membered heterocyclic ring. In embodiments, R11 and R13 taken together with the atoms to which they are attached form an optionally substituted 5- or 6-membered heterocyclic ring.
In embodiments, R14 is H, halogen, —OH, optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted heteroalkyl. In embodiments, R14 is H, halogen, or optionally substituted alkyl. In embodiments, R14 is H or alkyl. In some embodiments, R14 is H. In embodiments, R14 is alkyl. In embodiments, the alkyl is a C1-C5alkyl. In embodiments, the C1-C5 alkyl is s methyl, ethyl, or isopropyl. In embodiments, R14 is halogen. In embodiments, the halogen is Cl, Br, or F. In embodiments, the cycloalkyl is a C3-C6 cycloalkyl. In embodiments, the cycloalkyl is cyclopropyl. In embodiments, the optionally substituted heteroalkyl is —CH2—O—C1-5alkyl. In embodiments, the optionally substituted heteroalkyl is —CH2—N—(H)(C1-5alkyl) or —CH2—N—(C1-5alkyl)2.
In embodiments, the present disclosure provides a compound of Formula (I-B):
or a pharmaceutically acceptable salt thereof,
wherein:
E is N or C—ZR5, wherein no more than two of A, B, and E are N;
X, Y, and Z are each independently absent, O, S, or NH;
R1 and R2 are each independently H, D, optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted heteroalkyl;
R3, R4, and R5 are each independently H, D, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heteroalkyl, or —P(O)(OH)2;
R6 is H, optionally substituted alkyl, optionally substituted cycloalkyl, alkylene- optionally substituted cycloalkyl, or optionally substituted heteroalkyl;
R7 and R8 are each independently H, D, halogen, optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted heteroalkyl, or R7 and R8 taken together with the atom to which they are attached form an optionally substituted cycloalkyl ring;
R9 and R10 are each independently H, D, halogen, optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted heteroalkyl, or R9 and R10 taken together with the atom to which they are attached form an oxo;
R11 and R12 are each independently O−, —OH, —OD, —O-alkyl, —O-cycloalkyl, —O-alkylene-cycloalkyl, —O-aryl, or —OM, wherein M is a pharmaceutically acceptable cation, or R11 and R12 together with the atoms to which they are attached form a heterocyclyl, and the alkyl, cycloalkyl, aryl and heterocyclyl are each optionally substituted;
R13 is H, D, halogen, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl, alkylene-optionally substituted aryl, —C(O)-(alkylene- optionally substituted aryl), or —O—C(O)—NHR15, or R11 and R13 taken together with the atoms to which they are attached form an optionally substituted heterocyclic ring comprising 4-7 carbon atoms;
R14 is H, D, halogen, —OH, an optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted heteroalkyl; and
R15 is H, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl.
In embodiments, is the present disclosure provides a compound of Formula (II-B):
or a pharmaceutically acceptable salt thereof,
wherein:
E is N or C—ZR5, wherein no more than two of A, B, and E are N;
X, Y, and Z are each independently absent, O, S, or NH;
R1 and R2 are each independently H, D, optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted heteroalkyl;
R3, R4, and R5 are each independently H, D, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heteroalkyl, or —P(O)(OH)2;
R6 is H, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkylene-cycloalkyl, or optionally substituted heteroalkyl;
R7 and R8 are each independently H, D, halogen, optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted heteroalkyl, or R7 and R8 taken together with the atom to which they are attached form an optionally substituted cycloalkyl ring;
R9 and R10 are each independently H, D, halogen, —OH, optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted heteroalkyl, or R9 and R10 taken together with the atom to which they are attached form an oxo;
R12 is O−, —OH, —OD, —O-alkyl, —O-cycloalkyl, —O-alkylene-cycloalkyl, —O-aryl, or —OM, wherein M is a pharmaceutically acceptable cation, and the alkyl, cycloalkyl, and aryl are optionally substituted;
R14 is H, D, halogen, —OH, optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted heteroalkyl; and
n is 0, 1, or 2.
In embodiments, A is N. In embodiments, A is CH.
In embodiments, B is N. In embodiments, B is C—YR4.
In embodiments, E is N. In embodiments, E is C—ZR5.
In embodiments of Formula (I), W is NR6 or O. In embodiments, W is NR6 or S. In embodiments, W is O or S. In embodiments, W is NR6. In embodiments, W is O. In embodiments, W is S.
In embodiments, X, Y, and Z are each independently absent, O, S, or N(C1-5)alkyl. In embodiments, X, Y, and Z are each independently absent or O. In embodiments, X, Y, and Z are each independently absent or NH. In embodiments, X, Y, and Z are each independently absent or S. In embodiments, X, Y, and Z are each absent.
In embodiments, X is O, and Y and Z are absent. In embodiments, Y is G, and X and Z are absent. In embodiments, Z is O, and X and Y are absent. In embodiments, X is S, and Y and Z are absent. In embodiments, Y is S, and X and Z are absent. In embodiments, Z is S, and X and Y are absent. In embodiments, X is NH, and Y and Z are absent. In embodiments, Y is NH, and X and Z are absent. In embodiments, Z is NH, and X and Y are absent. In embodiments, X is N(C1-5)alkyl, and Y and Z are absent. In embodiments, Y is N(C1-5)alkyl, and X and Z are absent. In embodiments, Z is N(C1-5)alkyl, and X and Y are absent.
In embodiments, R1 and R2 are each independently H, optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted heteroalkyl. In embodiments, R1 and R2 are each independently H, optionally substituted C1-5alkyl, optionally substituted C3-6Cycloalkyl, or optionally substituted C1-5cycloalkyl heteroalkyl. In some embodiments, R1 and R2 are each independently H or alkyl. In embodiments, R1 and R2 are each independently H or C1-5alkyl. In embodiments, R1 and R2 are each alkyl. In embodiments, R1 and R2 are each C1-5alkyl. In embodiments, R1 and R2 are each independently methyl, ethyl, or isopropyl. In embodiments, R1 and R2 are each methyl. In embodiments, R1 and R2 taken together with the nitrogen to which they are attached form a 4- to 6-membered heterocyclyl, e.g., azetidine, pyrrolidine, or piperidine.
In embodiments, R3, R4, and R5 are each independently H, D, optionally substituted C1-5alkyl, optionally substituted C3-6cycloalkyl, optionally substituted C1-5heteroalkyl, —P(O)(OC1-5alkyl)2, —P(O)(OPh)2, or —P(O)(OH)2. In embodiments, R3, R4, and R5 are each independently H, optionally substituted C1-5alkyl, optionally substituted C3-6cycloalkyl, optionally substituted C1-5heteroalkyl, —P(O)(OC1-5alkyl)2, —P(O)(OPh)2, or —P(O)(OH)2. In embodiments, R3, R4, and R5 are each independently H, optionally substituted C1-5alkyl, optionally substituted C3-6cycloalkyl, —P(O)(OC1-5alkyl)2, —P(O)(OPh)2, or —P(O)(OH)2. In embodiments, R3, R4, and R5 are each independently H, optionally substituted C1-5alkyl, optionally substituted C3-6cycloalkyl, or —P(O)(OH)2. In embodiments, R3, R4, and R5 are each independently H, optionally substituted C1-5alkyl, or —P(O)(OH)2. In embodiments, the C1-5 alkyl is methyl, ethyl, propyl, isopropyl, or t-butyl. In embodiments, the C1-5alkyl is methyl, ethyl, or isopropyl. In embodiments, R3, R4, and R5 are each H.
In embodiments, R3 is optionally substituted C1-5alkyl or —P(O)(OH)2, and R4 and R5 are each H. In embodiments, R4 is optionally substituted C1-5alkyl or —P(O)(OH)2, and R3 and R5 are each H. In embodiments, R5 is optionally substituted C1-5alkyl or —P(O)(OH)2, and R3 and R4 are each H. In embodiments, the C1-5alkyl is methyl, ethyl, propyl, isopropyl, or t-butyl. In embodiments, the C1-5alkyl is methyl, ethyl, or isopropyl.
In embodiments, X is absent, and R3 is H, halogen, optionally substituted C1-5alkyl, optionally substituted C3-6cycloalkyl, or —P(O)(OH)2. In embodiments, Y is absent, and R4 is H, halogen, optionally substituted C1-5alkyl, optionally substituted C3-6cycloalkyl, or —P(O)(OH)2. In embodiments, Z is absent, and R3 is H, halogen, optionally substituted C1-5alkyl, optionally substituted C3-6cycloalkyl, or —P(O)(OH)2. In embodiments, the C1-5alkyl is methyl, ethyl, propyl, isopropyl, or t-butyl. In embodiments, the C1-5alkyl is methyl, ethyl, or isopropyl. In embodiments, the halogen is F, Cl, or Br.
In embodiments, R6 is H, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkylene-cycloalkyl, optionally substituted alkylene-heterocyclyl, or optionally substituted alkylene-aryl. In embodiments, R6 is H, optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted alkylene-cycloalkyl. In embodiments, the optionally substituted alkyl is an optionally substituted C1-5alkyl. In embodiments, the optionally substituted cycloalkyl is an optionally substituted C3-6cycloalkyl. In embodiments, the optionally substituted aryl is an optionally substituted phenyl. In embodiments, the optionally substituted heterocyclyl is an optionally substituted 4- to 6-membered heterocyclyl, e.g., an azetidine, pyrrolidine, piperidine, morpholine, thiomorpholine, piperazine, each of which is optionally substituted. In embodiments, the optionally substituted alkylene is an optionally substituted C1-3alkylene. In embodiments, the optionally substituted alkylene is an optionally substituted methylene. In embodiments, R6 is H, C1-5alkyl, C3-6cycloalkyl or C(═O)(C1-5 alkyl). In embodiments, R6 is H, C1-5alkyl, or C3-8 cycloalkyl. In embodiments, R6 is H or C1-5alkyl. In embodiments, R6 is H. In embodiments, R6 is C1-5alkyl. In embodiments, the C1-5alkyl is methyl, ethyl, propyl, isopropyl, or t-butyl. In embodiments, the optionally substituted C1-5alkyl is —C(O)—C1-4alkyl, —C(O)—N(H)(C1-4alkyl), or —C(O)—OC1-4alkyl.
In embodiments, R7 and R8 are each independently H, halogen, optionally substituted alkyl, —OH, optionally substituted —O-alkyl or optionally substituted —O— cycloalkyl. In embodiments, R7 and R8 are each independently H, halogen, optionally substituted C1-5alkyl, —OH, optionally substituted —OC1-5alkyl, or optionally substituted —O—C3-6cycloalkyl. In embodiments, R7 and R8 are each independently H or optionally substituted C1-5alkyl. In embodiments, R7 and R8 are each H. In embodiments, R7 and R8 are each optionally substituted C1-5alkyl. In embodiments, R7 and R8 are each halogen. In embodiments, the halogen is F. In embodiments, the C1-5alkyl is methyl, ethyl, or isopropyl. In embodiments, the C1-5alkyl is methyl. In embodiments, the C1-5alkyl is ethyl.
In embodiments, R7 and R8 taken together with the atom to which they are attached form an oxo or an optionally substituted cycloalkyl ring. In embodiments, R7 and R8 taken together with the atom to which they are attached form an oxo. In embodiments, R7 and R8 taken together with the atom to which they are attached form an optionally substituted cycloalkyl ring. In embodiments, the optionally substituted cycloalkyl ring is an optionally substituted C3-6cycloalkyl ring. In embodiments, the optionally substituted cycloalkyl ring is an optionally substituted cyclopropyl. In embodiments, R7 is H and R5 is optionally substituted C1-5alkyl. In embodiments, R7 is H and R5 is F. In embodiments, R7 is H and R5 is —OH. In embodiments, R7 is H and R5 is —OCH3. In embodiments, R7 is F and R5 is F. In embodiments, R7 and R8 are each optionally substituted C1-5alkyl. In embodiments, the C1-5alkyl is methyl.
In embodiments, R9 and R10 are each independently H, halogen, optionally substituted alkyl, —OH, optionally substituted —O-alkyl or optionally substituted —O— cycloalkyl. In embodiments, R9 and R10 are each independently H, halogen, optionally substituted C1-5alkyl, —OH, optionally substituted —OC1-5alkyl, or optionally substituted —O—C3-6cycloalkyl. In embodiments, R9 and R10 are each independently H or optionally substituted C1-5alkyl. In embodiments, R9 and R10 are each H. In embodiments, R9 and R10 are each optionally substituted C1-5alkyl. In embodiments, R9 and R10 are each halogen. In embodiments, the halogen is F. In embodiments, the C1-5alkyl is methyl, ethyl, or isopropyl. In embodiments, the C1-5alkyl is methyl. In embodiments, the C1-5alkyl is ethyl.
In embodiments, R9 and R10 taken together with the atom to which they are attached form an optionally substituted cycloalkyl ring. In embodiments, the optionally substituted cycloalkyl ring is an optionally substituted C3-6cycloalkyl ring. In embodiments, the optionally substituted cycloalkyl ring is an optionally substituted cyclopropyl. In embodiments, R9 is H and R10 is optionally substituted C1-5alkyl. In embodiments, R9 is H and R10 is F. In embodiments, R9 is H and R10 is —OH. In embodiments, R9 is H and R10 is —OCH3. In embodiments, R9 and R10 are each F. In embodiments, R9 and R10 are each optionally substituted C1-5alkyl. In embodiments, the C1-5alkyl is methyl.
In embodiments of Formula (I), R11 and R12 are each independently O−, —OH, optionally substituted —O-alkyl, optionally substituted —O-cycloalkyl, optionally substituted —O-alkylene-cycloalkyl, optionally substituted —O-aryl, or —OM, wherein M is a pharmaceutically acceptable cation. In embodiments, the optionally substituted —O-alkyl is an optionally substituted —O-haloalkyl, a hemiaminal, an acetal, or an amino acid residue. In embodiments, R11 and R12 are each independently O−, —OH, optionally substituted —O—C1-5alkyl, optionally substituted —O—C1-5haloalkyl, optionally substituted —O—C3-6cycloalkyl, or -OM. In embodiments, R11 and R12 are each independently O−, —OH, optionally substituted —O—C1-5alkyl, optionally substituted —O—C1-5haloalkyl, or -OM. In embodiments, R11 is O− and R12 is —OH, optionally substituted —O—C1-5alkyl, optionally substituted —O—C1-5haloalkyl, or -OM. In embodiments, R11 and R12 are each optionally substituted —O—C1-5alkyl. In embodiments, R11 and R12 are each optionally substituted —O—C1-3alkyl. In embodiments, R11 and R12 are each independently —OMe, —OEt, —OiPr, or -OtBu. In embodiments, R11 and R12 are each optionally substituted —O—C1-5haloalkyl. In embodiments, the —O—C1-5haloalkyl is —OCH3, —OCH2F, —OCHF2, or —OCH2CF3. In embodiments, the —O—C1-5haloalkyl is a —OCH2CF3. In embodiments, M is Na+, K+, NH4+, or Ca+2. In embodiments, M is Na+, K+, or NH4+.
In embodiments of Formula (I), R11 and R12 taken together with the atoms to which they are attached form a heterocyclyl. In embodiments, R11 and R12 taken together with the atoms to which they are attached form a 5- to 12-membered heterocyclyl. In embodiments, the heterocyclyl has the structure:
In embodiments of Formula (II), R12 is O−, —OH, optionally substituted —O-alkyl, optionally substituted —O-cycloalkyl, optionally substituted —O-alkylene-cycloalkyl, optionally substituted —O-aryl, or —OM, wherein M is a pharmaceutically acceptable cation. In embodiments, the optionally substituted —O-alkyl is an optionally substituted —O-haloalkyl, a hemiaminal, an acetal, or an amino acid residue. In embodiments, R12 is O−, —OH, —O-alkyl, —O-haloalkyl, —O-cycloalkyl, or -OM. In embodiments, R12 is O−, —OH, optionally substituted —O-alkyl, optionally substituted —O-haloalkyl, or -OM. In embodiments, R12 is O—, optionally substituted —O-alkyl, or optionally substituted —O-haloalkyl. In embodiments, R12 is optionally substituted —O-alkyl. In embodiments, the optionally substituted —O-alkyl is an optionally substituted —O—C1-5alkyl. In embodiments, the —O-alkyl is —OMe, —OEt, —OiPr, or -OtBu. In embodiments, R12 is —O-haloalkyl. In embodiments, the optionally substituted —O-haloalkyl is optionally substituted —O—C1-5haloalkyl. In some embodiments, the —O-haloalkyl is —OCH2CF3. In embodiments, R12 is O−, —OH, —O—C1-5alkyl, —O—C1-5haloalkyl, —O—C3-6cycloalkyl, or -OM. In embodiments, M is Na+, K+, NH4+, or Ca+2. In embodiments, M is Na+, K+, or NH4+. In embodiments, the —O-alkyl is —OMe, —OEt, —OiPr, or -OtBu. In embodiments, the —O—C1-5haloalkyl is —OCH3, —OCH2F, —OCHF2, or —OCH2CF3. In embodiments, the —O—C1-5haloalkyl is —OCH2CF3.
In embodiments, R13 is H, D, or C1-5alkyl. In embodiments, R13 is H or —C1-5alkyl. In embodiments, the C1-5alkyl is methyl, ethyl, propyl, isopropyl, or butyl. In embodiments, R13 is H, methyl, ethyl, or isopropyl.
In embodiments of Formula (I), R11 and R13 taken together with the atoms to which they are attached form an optionally substituted heterocyclic ring comprising 4-7 carbon atoms. In embodiments, R11 and R13 taken together with the atoms to which they are attached form an optionally substituted 5-to 7-membered heterocyclic ring. In embodiments, R11 and R13 taken together with the atoms to which they are attached form an optionally substituted 5- or 6-membered heterocyclic ring.
In embodiments, R14 is H, halogen, —OH, optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted heteroalkyl. In embodiments, R14 is H, halogen, or optionally substituted alkyl. In embodiments, R14 is H or alkyl. In some embodiments, R14 is H. In embodiments, R14 is alkyl. In embodiments, the alkyl is a C1-C5alkyl. In embodiments, the C1-C5 alkyl is s methyl, ethyl, or isopropyl. In embodiments, R14 is halogen. In embodiments, the halogen is Cl, Br, or F. In embodiments, the cycloalkyl is a C3-C6 cycloalkyl. In embodiments, the cycloalkyl is cyclopropyl. In embodiments, the optionally substituted heteroalkyl is —CH2—O—C1-5alkyl. In embodiments, the optionally substituted heteroalkyl is —CH2—N—(H)(C1-5alkyl) or —CH2—N—(C1-5alkyl)2.
In embodiments of Formula (I), R15 is H, optionally substituted C1-5alkyl, or optionally substituted phenyl.
In embodiment of Formula (II), n is 0 or 1. In embodiments, n is 0. In some embodiments, n is 1. In embodiments, n is 2.
In embodiments, provided herein is one or more compounds of Formula (I-A) or (I-B) selected from Table 1 or a pharmaceutically acceptable salt thereof.
In embodiments, provided herein is one or more compounds of Formula (I-A) or (I-B) selected from Table 2 or a pharmaceutically acceptable salt thereof.
In embodiments, provided herein is one or more compounds of Formula (II-A) or (II-B) selected from Table 3 or a pharmaceutically acceptable salt thereof.
In embodiments, provided herein is one or more compounds of Formula (II-A) or (II-B) selected from Table 4 or a pharmaceutically acceptable salt thereof.
In embodiments, provided herein is a compound of Formula (I-A), (I-B), (II-A), or (II-B) as described herein, wherein the Formulas (I-A), (I-B), (II-A), and (II-B) exclude the compounds described in International Application No. PCT/US2022/032918.
In embodiments of the present disclosure, a pharmaceutical composition comprises a therapeutically effective amount of one or more compounds of the present disclosure (e.g., compounds of Formula (I-A), Formula (I-B), Formula (II-A), Formula (II-B) or Compounds of Table 1, Table 2, Table 3, or Table 4) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.
The pharmaceutically acceptable excipients and adjuvants are added to the composition or formulation for a variety of purposes. In embodiments, a pharmaceutical composition comprising one or more compounds disclosed herein, or a pharmaceutically acceptable salt thereof, further comprise a pharmaceutically acceptable carrier. In embodiments, a pharmaceutically acceptable carrier includes a pharmaceutically acceptable excipient, binder, and/or diluent. In embodiments, suitable pharmaceutically acceptable carriers include, but are not limited to, inert solid fillers or diluents and sterile aqueous or organic solutions. In embodiments, suitable pharmaceutically acceptable excipients include, but are not limited to, water, salt solutions, alcohol, polyethylene glycols, gelatin, lactose, amylase, magnesium stearate, talc, silicic acid, viscous paraffin, and the like.
For the purposes of this disclosure, the compounds of the present disclosure can be formulated for administration by a variety of means including orally, parenterally, by inhalation spray, topically, or rectally in formulations containing pharmaceutically acceptable carriers, adjuvants and vehicles. The term parenteral as used here includes subcutaneous, intravenous, intramuscular, and intraarterial injections with a variety of infusion techniques. Intraarterial and intravenous injection as used herein includes administration through catheters.
In one aspect, the present disclosure provides methods of treating or preventing neurological disorders in a subject in need thereof, the methods comprising administering a therapeutically effective amount of a compound disclosed herein (e.g., compounds of Formula (I-A), Formula (I-B), Formula (II-A), Formula (II-B) or Compounds of Table 1, Table 2, Table 3, or Table 4), a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof to the subject.
In embodiments, the neurological disorder is a mood disorder. In embodiments, the mood disorder is clinical depression, postnatal depression or postpartum depression, perinatal depression, atypical depression, melancholic depression, psychotic major depression, cationic depression, seasonal affective disorder, dysthymia, double depression, depressive personality disorder, recurrent brief depression, major depressive disorder, minor depressive disorder, bipolar disorder or manic depressive disorder, depression caused by chronic medical conditions, treatment-resistant depression, refractory depression, suicidality, suicidal ideation, or suicidal behavior. In embodiments, the method described herein provides therapeutic effect to a subject suffering from depression (e.g., moderate or severe depression). In embodiments, the mood disorder is associated with neuroendocrine diseases and disorders, neurodegenerative diseases and disorders (e.g., epilepsy), movement disorders, tremor (e.g., Parkinson's Disease), or women's health disorders or conditions. In embodiments, the mood disorder is depression. In embodiments, the mood disorder is treatment-resistant depression or major depressive disorder. In embodiments, the mood disorder is major depressive disorder. In embodiments, the mood disorder is treatment-resistant depression.
In embodiments, the present disclosure provides methods of treating or preventing PTSD, mood disorders, general anxiety disorder, addictive disorders, and/or drug dependence in a subject in need thereof, the methods comprising administering a therapeutically effective amount of a compound disclosed herein (e.g., compounds of Formula (I-A), Formula (I-B), Formula (II-A), Formula (II-B) or Compounds of Table 1, Table 2, Table 3, or Table 4), a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof to the subject.
In embodiments, the present disclosure provides methods of treating or preventing PTSD in a subject in need thereof, the methods comprising administering a therapeutically effective amount of a compound disclosed herein (e.g., compounds of Formula (I-A), Formula (I-B), Formula (II-A), Formula (II-B) or Compounds of Table 1, Table 2, Table 3, or Table 4), a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof to the subject.
In embodiments, the methods include treating PTSD through induction and maintenance therapy by administering a compound disclosed herein, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof. In embodiments, the compounds of the present disclosure are used for induction and maintenance therapy to treat PTSD with an improved safety profile when compared to treatment with the entactogenic, oneirophrenic or psychedelic compound (e.g., dimethyltryptamine or related compound, psilocybin, or MDMA) alone.
In embodiments, the present disclosure provides methods of treating or preventing behavioral or mood disorders in a subject in need thereof, the methods comprising administering a therapeutically effective amount of a compound disclosed herein (e.g., compounds of Formula (I-A), Formula (I-B), Formula (II-A), Formula (II-B) or Compounds of Table 1, Table 2, Table 3, or Table 4), a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof to the subject. In embodiments, the behavioral or mood disorder includes anxiety, such as social anxiety in autistic subjects (e.g., autistic adults) and anxiety related to life-threatening illnesses. In embodiments, the behavioral or mood disorder includes stress (where moderation thereof is measured, e.g., by effects on amygdala responses). In embodiments, the anxiety disorder is panic disorder, obsessive-compulsive disorder, and/or general anxiety disorder. In embodiments, the subject suffers from a lack of motivation, attention, lack of accuracy in memory recall, speed of response, perseveration, and/or cognitive engagement. Further examples include depression (e.g., MDD or TRD), attention disorders, disorders of executive function and/or cognitive engagement, obsessive compulsive disorder, bipolar disorder, panic disorder, phobia, schizophrenia, psychopathy, antisocial personality disorder and/or neurocognitive disorders.
In embodiments, the present disclosure provides methods for treating an addictive disorder in a subject in need thereof, the methods comprising administering a therapeutically effective amount of a compound disclosed herein (e.g., compounds of Formula (I-A), Formula (I-B), Formula (II-A), Formula (II-B) or Compounds of Table 1, Table 2, Table 3, or Table 4), a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof to the subject. In embodiments, the addictive disorder is alcohol abuse, substance abuse, smoking, obesity, or mixtures thereof. In embodiments, the disorder is an eating disorder (e.g., anorexia nervosa, bulimia, nervosa, binge eating disorder, etc.) or an auditory disorder.
In embodiments, the present disclosure provides methods for treating an impulsive disorder in a subject in need thereof, the methods comprising administering a therapeutically effective amount of a compound disclosed herein (e.g., compounds of Formula (I-A), Formula (I-B), Formula (II-A), Formula (II-B) or Compounds of Table 1, Table 2, Table 3, or Table 4), a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof to the subject. In embodiments, the impulsive disorder is attention deficit hyperactivity disorder (ADHD), attention deficit disorder (ADD), Tourette's syndrome, autism, or combinations thereof.
In embodiments, the present disclosure provides methods for treating a compulsive disorder in a subject in need thereof, the methods comprising administering a therapeutically effective amount of a compound disclosed herein (e.g., compounds of Formula (I-A), Formula (I-B), Formula (II-A), Formula (II-B) or Compounds of Table 1, Table 2, Table 3, or Table 4), a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof to the subject. In embodiments, the compulsive disorder is obsessive compulsive disorder (OCD), gambling, aberrant sexual behavior, or combinations thereof.
In embodiments, the present disclosure provides methods for treating a personality disorder in a subject in need thereof, the methods comprising administering a therapeutically effective amount of a compound disclosed herein (e.g., compounds of Formula (I-A), Formula (I-B), Formula (II-A), Formula (II-B) or Compounds of Table 1, Table 2, Table 3, or Table 4), a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof. In embodiments, the personality disorder is conduct disorder, antisocial personality, aggressive behavior, or combinations thereof to the subject.
1. A compound of Formula (I-B)
or a pharmaceutically acceptable salt thereof,
wherein:
60. The compound of any one of embodiments 1-59, wherein R13 is H, D, or C1-5alkyl.
61. The compound of any one of embodiments 1-60, wherein R13 is H or C1-5alkyl.
62. The compound of any one of embodiments 1-60, wherein R13 is H, methyl, ethyl, or isopropyl.
63. The compound of any one of embodiments 1-60, wherein R14 is H, F, Cl, Br or methyl.
64. The compound of any one of embodiments 1-63, wherein R14 is H.
65. The compound of embodiment 1, having the structure:
or a pharmaceutically acceptable salt thereof.
66. The compound of embodiment 1, having the structure:
or a pharmaceutically acceptable salt thereof,
67. A compound of Formula (II-B):
or a pharmaceutically acceptable salt thereof,
or a pharmaceutically acceptable salt thereof.
127. The compound of any one of embodiments 1-66, wherein the compound of Formula (I) excludes the compounds described in International Application No. PCT/US2022/032918.
128. The compound of any one of embodiments 67-126, wherein the compound of Formula (II) excludes the compounds described in International Application No. PCT/US2022/032918.
129. A compound of Formula (I-A):
or a pharmaceutically acceptable salt thereof,
wherein:
A is N or C—VR16;
B is N or C—YR4;
E is N or C—ZR5, wherein no more than two of A, B, and E are N;
W is O, S, or NR6;
V, X, Y, and Z are each independently absent, O, S, or NH;
R1 and R2 are each independently H, D, deuterated alkyl, optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted heteroalkyl;
R3, R4, R5, and R16 are each independently H, D, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heteroalkyl, or —P(O)(OH)2;
R6 is H, optionally substituted alkyl, optionally substituted cycloalkyl, alkylene-optionally substituted cycloalkyl, or optionally substituted heteroalkyl;
R7 and R8 are each independently H, D, halogen, optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted heteroalkyl, or R7 and R8 taken together with the atom to which they are attached form an optionally substituted cycloalkyl ring;
R9 and R10 are each independently H, D, halogen, optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted heteroalkyl, or R9 and R10 taken together with the atom to which they are attached form an oxo;
R11 and R12 are each independently alkyl, deuterated alkyl, —O—, —OH, —OD, —O-alkyl, —O-cycloalkyl, —O-alkylene-cycloalkyl, —O-aryl, or —OM, wherein M is a pharmaceutically acceptable cation, or R11 and R12 together with the atoms to which they are attached form a heterocyclyl, and the alkyl, cycloalkyl, aryl and heterocyclyl are each optionally substituted;
R13 is H, D, halogen, deuterated alkyl, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl, alkylene-optionally substituted aryl, —C(O)-(alkylene- optionally substituted aryl), or -G-C(O)—NHR15, or R11 and R13 taken together with the atoms to which they are attached form an optionally substituted heterocyclic ring comprising 4-7 carbon atoms;
R14 is H, D, halogen, haloalkyl, —OH, an optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted heteroalkyl; and
R15 is H, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl, wherein the compound is not:
Compounds of the present disclosure can be synthesized using the following exemplary methods or other methods that are known to those skilled in the art.
General reaction conditions are provided, and reaction products can be purified by known methods including silica gel chromatography using various organic solvents such as hexane, dichloromethane, ethyl acetate, methanol and the like or preparative reverse phase high pressure liquid chromatography.
Preparation of compounds can involve the protection and deprotection of various chemical groups. The need for protection and deprotection, and the selection of appropriate protecting groups can be readily determined by one skilled in the art. The chemistry of protecting groups can be found, for example, in Greene and Wuts, Protective Groups in Organic Synthesis, 44th. Ed., Wiley & Sons, 2006, as well as in Jerry March, Advanced Organic Chemistry, 4th edition, John Wiley & Sons, publisher, New York, 1992 which are incorporated herein by reference in their entirety.
Compounds 1-10 of Table 5 were prepared as described by the methods below.
Compounds 1-4 were synthesized from a commercially available intermediate tryptophan according to Scheme 1.
Compounds 5 and 6 were synthesized from commercially available intermediate 5-substituted tryptophan according to Scheme 2.
Salts of the disclosed compounds were synthesized in one step from compound 1 as shown in Scheme 3.
Step 1. To a solution of tryptamine (200 mg, 1.25 mmol, 1.0 equiv) in 3 mL of methanol was added sodium cyanoborohydride (197 mg, 3.13 mmol, 2.5 equiv), acetic acid (0.15 mL) and formaldehyde (254 mg, 3.13 mol, 2.5 equiv, 37% aq. solution) in methanol (1.5 mL) at 0° C. The mixture solution was stirred overnight at 25° C. and then concentrated under vacuum. The resulting solution was diluted with 20 mL of saturated sodium bicarbonate and extracted with ethyl acetate (3×20 mL). The combined organic layers were washed with brine (2×20 mL) of, dried over anhydrous sodium sulfate and concentrated under vacuum. The resulting mixture was dissolved in 2 mL of acetonitrile, then di-tert-butyl (chloromethyl) phosphate (274 mg, 1.06 mmol, 2.0 equiv), Me5-piperidine (164.5 mg, 1.06 mmol, 2.0 equiv) and sodium iodide (8.0 mg, 0.05 mmol, 0.1 equiv) was added at 25° C. under nitrogen atmosphere. The mixture was stirred for 24 h at 40° C. The resulting solution was diluted with 20 mL of ethyl acetate and washed sequentially with saturated sodium bicarbonate solution (2×10 mL) and saturated sodium chloride solution (10 mL). The combined organic layers were washed with brine (2×20 mL), dried over anhydrous sodium sulfate, and concentrated under vacuum. The crude product (120 mg) was used in the next step directly without further purification.
Step 2. To a solution of intermediate (120 mg, 0.29 mmol, 1.0 equiv) from above Step 1 in dichloromethane (1.2 mL) under argon was added trifluoroacetic acid (0.6 mL) slowly at RT. The resulting solution was stirred for 1 h and then concentrated under reduced pressure. The crude product was purified by reverse phase-chromatography: Column, C18 silica gel; mobile layer, water, and methanol (20% to 100% methanol over 15 min and hold 100% for 5 min); Detector, 220 nm. The fractions were concentrated under reduced pressure. Compound 1 was obtained as a white solid (28 mg, 28%). MS m/z [M+H]+ (ESI): 299.05. 1H NMR (300 MHz, DMSO-d6) δ 11.11 (s, 1H), 7.65 (d, J=7.8 Hz, 1H), 7.37 (d, J=8.1 Hz, 1H), 7.26 (s, 1H), 7.11-6.98 (m, 2H), 4.89 (d, J=8.7 Hz, 2H), 3.51-3.45 (m, 2H), 3.18-3.13 (m, 2H), 3.07 (s, 6H). 31P NMR (121 MHz, DMSO-d6) δ−1.88.
To a solution of Compound 1 (100 mg, 0.34 mmol, 1.00 equiv) in N,N-Dimethylformamide (1 mL) was added 2-Iodopropane (171 mg, 1.00 mmol, 3.0 equiv) and trimethylamine (101 mg, 1.00 mmol, 3.0 equiv) at 25° C. The resulting mixture was stirred overnight at 50° C. and then diluted with 20 mL of dichloromethane. The organic layer was washed with saturated aqueous sodium chloride solution (2×20 mL) and dried over anhydrous sodium sulfate. The resulting solution was concentrated under reduced pressure and purified by reverse-phase: Column, C18 silica gel; mobile phase, water (with 0.05% NH4CO3), 10% to 100% gradient in 20 min; detector, UV 254 nm. Compound 2 was obtained as a white solid (20 mg, 17%) of: MS m/z [M+H]+ (ESI): 341.05. 1H NMR (400 MHz, DMSO-d6) δ 10.98 (s, 1H), 7.65 (d, J=8.0 Hz, 1H), 7.36 (d, J=8.0 Hz, 1H), 7.26 (d, J=2.0 Hz, 1H), 7.12-7.08 (m, 1H), 7.03-6.99 (m, 1H), 4.87 (d, J=8.8 Hz, 2H), 4.29-4.22 (m, 1H), 3.50-3.45 (m, 2H), 3.19-3.15 (m, 2H), 3.08 (s, 6H), 1.12 (d, J=6.0 Hz, 6H).
In a similar manner described for Compound 2, Compound 3 was prepared from 100 mg of Compound 1 and 156 mg of iodoethane Compound 3 was obtained as a white solid (19 mg 17%). MS m/z [M+H]+ (ESI): 327.05. 1H NMR (400 MHz, DMSO-d6) δ 10.98 (s, 1H), 7.65 (d, J=7.6 Hz, 1H), 7.36 (d, J=8.0 Hz, 1H), 7.26-7.00 (m, 3H), 4.88 (d, J=8.8 Hz, 2H), 3.77-3.69 (m, 2H), 3.50-3.44 (m, 2H), 3.20-3.15 (m, 2H), 3.08 (s, 6H), 1.13-1.04 (m, 3H).
In a similar manner described for Compound 2, Compound 4 was prepared from 100 mg of Compound 1 and 156 mg of iodomethane. The reaction was purified by Preparative-HPLC: Column: YMC Triart C18 ExRS, 20*150 mm, 5 μm; Mobile Phase A: 10 mmol NH4HCO3+0.05% NH3·H2O, Mobile Phase B: ACN; Flow rate: 20 mL/min; Gradient: 10% B to 34% B in 12 min, 34% B; Wavelength: 220 nm. Compound 4 was obtained as a white solid (19 mg). MS m/z [M+H]+ (ESI): 313.10. 1H NMR (300 MHz, DMSO-d6) δ 11.00 (s, 1H), 7.65 (d, J=7.8 Hz, 1H), 7.37 (d, J=7.8 Hz, 1H), 7.26 (d, J=2.1 Hz, 1H), 7.10-7.02 (m, 2H), 4.89 (d, J=8.4 Hz, 2H), 3.52 (s, 3H), 3.42-3.40 (m, 2H), 3.20-3.09 (m, 8H).
To a solution of 5-hydroxytryptamine (1 g, 5.2 mmol, 1.0 equiv) in methanol (10 mL) was added sodium cyanoborohydride (0.83 g, 13 mmol, 2.5 equiv), acetic acid (0.5 mL) and formaldehyde (1.1 mL, 13 mol, 2.5 equiv, 40% in water) at 0° C. The mixture solution was stirred overnight at 25° C. and then concentrated under vacuum. The crude product was dissolved in 2 mL of acetonitrile, then di-tert-butyl (chloromethyl) phosphate (480 mg, 1.9 mmol, 2.0 equiv), Me5-piperidine (330 mg, 1.9 mmol, 2.0 equiv) and sodium iodide (15 mg, 0.2 mmol, 0.1 equiv) was added at 25° C. under nitrogen. The mixture was stirred for 24 h at 40° C. The resulting solution was diluted with ethyl acetate (20 mL) and washed with saturated sodium bicarbonate solution (2×10 mL) and saturated sodium chloride solution (10 mL), respectively. The combined organic layers were washed with brine (2×20 mL) and dried over anhydrous sodium sulfate. The resulting solution was concentrated under reduced pressure and purified by Preparative-HPLC: Column: XBridge Prep Phenyl OBD Column, 19*250 mm, 5 μm; Mobile Phase A: 10 mmol NH4HCO3+0.05% NH3—H2O, Mobile Phase B: ACN; Flow rate: 60 mL/min; Gradient: 20% B to 50% B in 8 min, 50% B; Wavelength: 254 nm. Compound 5 was obtained as a white solid (38 mg). MS m/z [M+H]+ (ESI): 371.15. 1H NMR (300 MHz, DMSO-d6) δ 10.79 (s, 1H), 9.35 (s, 1H), 7.16-7.09 (m, 3H), 6.64-6.60 (m, 1H), 4.92 (d, J=8.1 Hz, 2H), 3.50-3.48 (m, 2H), 3.07-3.02 (m, 8H), 1.33 (s, 9H).
To a solution of 5-Methoxytryptamine (1 g, 5.2 mmol, 1.0 equiv) in methanol (10 mL) was added sodium cyanoborohydride (0.83 g, 13 mmol, 2.5 equiv), acetic acid (0.5 mL) and formaldehyde (1.1 mL, 13 mol, 2.5 equiv, 40% in water) at 0° C. The mixture solution was stirred overnight at 25° C. and then concentrated under vacuum. The crude product was dissolved in 2 mL of acetonitrile, then di-tert-butyl (chloromethyl) phosphate (480 mg, 1.9 mmol, 2.0 equiv), Me5-piperidine (330 mg, 1.9 mmol, 2.0 equiv) and sodium iodide (15 mg, 0.2 mmol, 0.1 equiv) was added at 25° C. under nitrogen atmosphere. The mixture was stirred for 24 h at 40° C. The resulting solution was diluted with ethyl acetate (20 mL) and washed with saturated sodium bicarbonate solution (2×10 mL) and saturated sodium chloride solution (10 mL), respectively. The combined organic layers were washed with brine (2×20 mL) and dried over anhydrous sodium sulfate. The resulting solution was concentrated under reduced pressure and purified by Preparative-HPLC: Column: XBridge Prep OBD C18 Column, 30*150 mm, 5 μm; Mobile Phase A: Water (10 mmol/L NH4HCO3+0.1% NH3—H2O), Mobile Phase B: ACN; Flow rate: 60 mL/min; Gradient: 5% B to 35% B in 9 min, 35% B; Wavelength: 220 nm. Compound 6 was obtained as a white solid (31 mg). MS m/z [M+H]+ (ESI): 385.20. 1H NMR (400 MHz, DMSO-d6) δ 10.88 (s, 1H), 7.27-7.15 (m, 3H), 6.75-6.72 (m, 1H), 4.86 (d, J=8.7 Hz, 2H), 3.79 (s, 3H), 3.48-3.43 (m, 2H), 3.15-3.10 (m, 2H), 3.08 (s, 6H), 1.31 (s, 9H).
To a solution of Compound 1 (40 mg, 0.13 mmol, 1.00 equiv) in water (1 mL) were added sodium hydroxide (5.3 mg, 0.13 mmol, 1.0 equiv) at 25° C. The mixture was stirred for 15 min at 25° C. and the resulting solution was concentrated by lyophilization.) of Compound 7 was obtained as a white solid (30.0 mg, 70%). MS m/z [M+H]+ (ESI): 299.05. 1H NMR (400 MHz, Deuterium Oxide) δ 7.57-7.52 (m, 1H), 7.43-7.39 (m, 1H), 7.18-7.13 (m, 2H), 7.11-7.06 (m, 1H), 4.66 (d, J=6.4 Hz, 2H), 3.38-3.31 (m, 2H), 3.07-3.01 (m, 2H), 2.92 (s, 6H).
To a solution of Compound 1 (40 mg, 0.13 mmol, 1.0 equiv) in water (1 mL) were added potassium hydroxide (7 mg, 0.13 mmol, 1.0 equiv) at 25° C. The mixture was stirred for 15 min at 25° C. and the resulting solution was concentrated by lyophilization. Compound 8 was obtained as a white solid (32 mg, 71%). MS m/z [M+H]+ (ESI): 299.05. 1H NMR (400 MHz, Deuterium Oxide) δ 7.57-7.52 (m, 1H), 7.43-7.39 (m, 1H), 7.18-7.13 (m, 2H), 7.11-7.06 (m, 1H), 4.66 (d, J=6.4 Hz, 2H), 3.38-3.31 (m, 2H), 3.07-3.01 (m, 2H), 2.92 (s, 6H).
To a solution of Compound 1 (40 mg, 0.13 mmol, 1.00 equiv) in water (1 mL) were added ammonium hydroxide (23 mg, 0.13 mmol, 1.0 equiv) at 25° C. The mixture was stirred for 15 min at 25° C. and the resulting solution was concentrated by lyophilization. Compound 9 was obtained as a yellow solid (28 mg, 70%). MS m/z [M+H]+ (ESI): 299.05. 1H NMR (400 MHz, Methanol-d4) δ 7.69-7.61 (m, 1H), 7.39-7.34 (m, 1H), 7.24 (s, 1H), 7.16-7.04 (m, 2H), 4.92-4.90 (m, 2H), 3.67-3.57 (m, 2H), 3.32-3.27 (m, 2H), 3.17 (s, 6H).
To a solution of Compound 1 (40 mg, 0.13 mmol, 1.00 equiv) in water (1 mL) were added calcium hydroxide (5 mg, 0.07 mmol, 0.5 equiv) at 25° C. The mixture was stirred for 15 min at 25° C. and the resulting solution was concentrated by lyophilization. Compound 10 was obtained as a white solid (33 mg, 72%). MS m/z [M+H]+ (ESI): 299.05. 1H NMR (300 MHz, Deuterium Oxide) δ 7.52-7.47 (m, 1H), 7.38-7.33 (m, 1H), 7.15-7.00 (m, 3H), 4.62-4.61 (m, 2H), 3.36-3.25 (m, 2H), 3.06-2.94 (m, 2H), 2.88 (s, 6H).
Compound 1 was synthesized as part of a novel prodrug strategy for improving the water solubility of tertiary amine-containing drugs. As shown in the above scheme, tertiary amine DMT (parent) was converted in two-step reaction to the polar Intermediate Prodrug 1.
Intermediate Prodrug 1 releases the parent DMT in vivo through a two-step bio-reversion process. The rate determining first step is via an enzymatic process, where prodrug bio-reversion involves a phosphatase-catalyzed dephosphorylation to give the resultant hydroxymethyl quaternary ammonium intermediate and inorganic phosphate. The second step involves conversion of the hydroxymethyl quaternary ammonium intermediate chemically to DMT and formaldehyde at physiological pH.
Chemical and plasma stability of prodrug Compound 1 was evaluated and the results enumerated in Table 7 and Table 8, respectively. PK studies of prodrug Compound 1 and metabolite (VLS-02-23-10) in mice were also conducted and both plasma exposure and brain exposure were analyzed as shown in
The present application claims priority to U.S. Provisional Patent Application No. 63/387,679 filed Dec. 15, 2022, and which is hereby incorporated by reference in its entirety.
| Number | Date | Country | |
|---|---|---|---|
| 63387679 | Dec 2022 | US |
